Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rema Raman

Showing results (111-120 of 200) with videos related to

Pageof 20
Sort By:
Neurology. Clinical Practice|April 8, 2024
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized TrialJoshua D Grill, Rema Raman, Karin Ernstrom, et al.
Science (New York, N.Y.)|February 26, 2005
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's diseaseGorazd B Stokin, Concepción Lillo, Tomás L Falzone, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort studyKenichiro Sato, Ryoko Ihara, Kazushi Suzuki, et al.
Alzheimer'S Research & Therapy|June 12, 2015
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's diseaseRachelle S Doody, Rema Raman, Reisa A Sperling, et al.
Neurology|December 17, 2013
Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletesThomas W McAllister, James C Ford, Laura A Flashman, et al.
Annals of Neurology|October 13, 2023
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer DiseaseJoshua D Grill, Charlene Flournoy, Shobha Dhadda, et al.
Alzheimer'S Research & Therapy|June 30, 2015
Alzheimer's disease progression by geographical region in a clinical trial settingDavid B Henley, Sherie A Dowsett, Yun-Fei Chen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trialJoshua D Grill, Rema Raman, Charlene Flournoy, et al.
Journal of the American Heart Association|September 25, 2025
Evaluating the Science of Diversity in Clinical Trials: Design and Goals of an American Heart Association Strategic Focused Research NetworkErin D Michos, Cheryl R Himmelfarb, Eldrin F Lewis, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 19, 2021
Impact of the COVID-19 pandemic on statistical design and analysis plans for multidomain intervention clinical trials: Experience from World-Wide FINGERSSusanne Röhr, Hidenori Arai, Francesca Mangialasche, et al.
Pageof 20

Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
Neurology. Clinical Practice|April 8, 2024
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized TrialJoshua D Grill, Rema Raman, Karin Ernstrom, et al.
Science (New York, N.Y.)|February 26, 2005
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's diseaseGorazd B Stokin, Concepción Lillo, Tomás L Falzone, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort studyKenichiro Sato, Ryoko Ihara, Kazushi Suzuki, et al.
Alzheimer'S Research & Therapy|June 12, 2015
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's diseaseRachelle S Doody, Rema Raman, Reisa A Sperling, et al.
Neurology|December 17, 2013
Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletesThomas W McAllister, James C Ford, Laura A Flashman, et al.
Annals of Neurology|October 13, 2023
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer DiseaseJoshua D Grill, Charlene Flournoy, Shobha Dhadda, et al.
Alzheimer'S Research & Therapy|June 30, 2015
Alzheimer's disease progression by geographical region in a clinical trial settingDavid B Henley, Sherie A Dowsett, Yun-Fei Chen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trialJoshua D Grill, Rema Raman, Charlene Flournoy, et al.
Journal of the American Heart Association|September 25, 2025
Evaluating the Science of Diversity in Clinical Trials: Design and Goals of an American Heart Association Strategic Focused Research NetworkErin D Michos, Cheryl R Himmelfarb, Eldrin F Lewis, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 19, 2021
Impact of the COVID-19 pandemic on statistical design and analysis plans for multidomain intervention clinical trials: Experience from World-Wide FINGERSSusanne Röhr, Hidenori Arai, Francesca Mangialasche, et al.
Pageof 20